Q1 Earnings Estimate for ANRO Issued By HC Wainwright

Key Points

• HC Wainwright estimates Q1 2027 EPS of ($0.78), reiterates a "Buy" rating with a $50 target and projects full-year EPS of ($2.54) alongside quarterly losses for Q2–Q4 2027.
• The consensus among analysts is a Moderate Buy with a $35.14 target; ANRO traded at $21.11 (market cap ~$674M) and recently beat estimates with Q EPS of ($0.45) versus a consensus of ($0.56), reflecting mixed sentiment despite some institutional inflows.

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Alto Neuroscience in a research note issued on Thursday, April 2nd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.78) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q2 2027 earnings at ($0.85) EPS, Q3 2027 earnings at ($0.91) EPS and Q4 2027 earnings at ($0.90) EPS.

Other analysts also recently issued research reports about the company. Jefferies Financial Group restated a "buy" rating and issued a $35.00 target price on shares of Alto Neuroscience in a research report on Monday, March 16th. JonesTrading decreased their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating on the stock in a research note on Thursday, April 2nd. Robert W. Baird lowered their price objective on shares of Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating for the company in a report on Thursday, April 2nd. BTIG Research upped their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, February 17th. Finally, Wedbush reduced their target price on shares of Alto Neuroscience from $22.00 to $21.00 and set a "neutral" rating on the stock in a report on Thursday, April 2nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.14.

Alto Neuroscience Price Performance

Shares of ANRO traded down $1.42 during midday trading on Tuesday, reaching $21.11. The stock had a trading volume of 108,239 shares, compared to its average volume of 255,021. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $674.46 million, a price-to-earnings ratio of -9.71 and a beta of 2.01. The company's 50-day moving average is $19.40 and its 200 day moving average is $15.09. Alto Neuroscience has a 12-month low of $1.90 and a 12-month high of $25.17.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its earnings results on Monday, March 16th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.11.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANRO. Invesco Ltd. bought a new stake in Alto Neuroscience during the 1st quarter valued at $67,000. AQR Capital Management LLC bought a new stake in Alto Neuroscience in the 1st quarter worth $52,000. Marshall Wace LLP increased its position in shares of Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company's stock valued at $2,062,000 after acquiring an additional 84,417 shares during the period. Armistice Capital LLC increased its position in shares of Alto Neuroscience by 1.5% in the second quarter. Armistice Capital LLC now owns 1,624,000 shares of the company's stock valued at $3,573,000 after acquiring an additional 24,000 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Alto Neuroscience during the second quarter valued at about $240,000.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.